Skip to main content

Table 1 Baseline characteristics

From: Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis

Variable Mean ± SD
Age (years) 62.0 ± 12.3
Sex (male/female) 12/8
Primary disease
 Chronic glomerulonephritis, n (%) 7 (35.0)
 Diabetic nephropathy, n (%) 5 (25.0)
 Nephrosclerosis, n (%) 3 (15.0)
 Unknown, n (%) 5 (25.0)
Duration of hemodialysis (years) 7.8 ± 9.6